Navigation Links
Radient Pharmaceuticals' Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
Date:12/5/2011

TUSTIN, Calif., Dec. 5, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation  (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that the two abstracts it submitted to the 2012 Gastrointestinal Cancers Symposium (ASCO Conference) were accepted for presentation from among 730 abstracts submitted. The meeting will be held on January 19-21, 2012 at the Moscone West Building in San Francisco, California. Dr. Afsaneh Motamed-Khorasani, the Director of Oncology at Radient, will be presenting the data.

These two abstracts were the results of a collaborative study in the United States that compared the combined use of Onko-Sure® with carcinoembryonic antigen (CEA), the routine blood biomarker for colorectal cancer (CRC), and CEA alone. The clinical trial included a total of 564 subjects. Radient's proprietary Onko-Sure® cancer blood test combined with CEA test were more effective for the detection of colorectal cancer compared to using CEA test alone (an increase of 56% in the test sensitivity). Furthermore, the combined usage of Onko-Sure® and CEA in monitoring CRC recurrence showed a significant clinical advantage in terms of sensitivity (an increase of 35% in the test sensitivity). This was in line with a previous UK study published in peer reviewed journals in 2010.

Onko-Sure® has already been cleared by the US FDA for the monitoring of the treatment and recurrence in CRC. "We believe that Onko-Sure® provides a platform technology that is highly effective in the monitoring of colorectal cancer. Should an in vitro diagnostics test increase early detection of CRC recurrence when used adjunctively with other available diagnostic markers, the number of annual deaths due to CRC recurrence could be reduced. An increase in early detection has the potential to lead to an increased survival rate of patients," stated Radient Pharmaceuticals Chairman and CEO Douglas MacLellan.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Paul Knopick at: pknopick@eandecommunications.com or 949-707-5365.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Radient Contact:

Paul Knopick
E & E Communications
pknopick@eandecommunications.com
(Tel:) 949.707.5365


'/>"/>
SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Radient Pharmaceuticals Corporation Receives $500,000 in New Capital
2. Radient Pharmaceuticals Corporation Completes Restructurings with Institutional Investors to Limit Conversions and Stock Sales and Provide for Potential Additional Capital
3. Radient Pharmaceuticals Asks DHS Holding Co. to Retract News Release Saying It Will Enter Into Talks With Radient Pharmaceuticals Corporation
4. Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
5. Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX
6. Radient Pharmaceuticals Corporation Joins OTCQX
7. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
8. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021
9. Arbor Pharmaceuticals Announces Filing of First NDA
10. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)... --   , Study met ... cleansing and superiority in , Excellent ... of the ascending colon   , ... Norgine B.V. today announced new positive data from the phase III ... versus standard 2 litre PEG with ascorbate. The study met both ...
(Date:5/24/2016)... , May 24, 2016  Joe Marziani has joined VMS BioMarketing as senior ... executive officer, today. In his new role, Marziani will lead the company,s business development ... professionals to improve outcomes. Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... With a ... medical and food industries. Aside from its GMP accreditation, Validation Center is also ... successfully certified products, services and staff. , Validation Center is ISO17025 accredited and ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research ... their dogs straight off the grill. Of the 90 percent of Americans who say ... a hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University College of ... programs. , Answering to the increasing demand for curricular specializations, the Certificate in ... environmental and land use law. ,  , “The demand for lawyers with specific ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card ... the country. The nonprofit Hope For Heroes partnered with the leading provider of ... disabled military veterans, as well as police, firemen, and EMS professionals across the country, ...
Breaking Medicine News(10 mins):